Non-Therapeutic Biomolecules Market Report 2025

The non-therapeutic biomolecules market size has grown rapidly in recent years. It will grow from $30.76 billion in 2024 to $34.23 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to increased research and development (R&D) investments, growing applications in research and diagnostics, rising awareness and adoption, strategic collaborations and partnerships, regulatory support.

The non-therapeutic biomolecules market size is expected to see rapid growth in the next few years. It will grow to $52.15 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to emerging market opportunities, advancements in data analytics and integration, growing focus on precision medicine, increasing investment in personalized healthcare, expanding application areas. Major trends in the forecast period include technological advancements, strategic collaborations, rising applications in agriculture, expanding role in industrial processes, customization and personalization.

The rapidly growing number of research studies and laboratory tests is expected to drive the growth of the non-therapeutic biomolecules market. Laboratory testing involves analyzing samples of blood, urine, or other bodily substances to diagnose and monitor diseases and develop treatment plans, while research focuses on generating new knowledge or creatively applying existing knowledge to form new concepts, theories, and understandings. Non-therapeutic biomolecules are utilized in laboratory testing to measure the presence or concentration of biomarker molecules that indicate disease, thereby enhancing the sensitivity and specificity of tests. For example, in July 2024, the National Health Service (NHS), a UK-based healthcare provider, reported that diagnostic activities surpassed pre-pandemic levels in 2023, with a 21% increase in tests conducted in May 2024 compared to the previous year. Thus, the increasing volume of research and laboratory testing is propelling the growth of the non-therapeutic biomolecules market.

The rise in healthcare expenditure is anticipated to drive the growth of the non-therapeutic biomolecules market in the coming years. Increased spending on healthcare often results in greater funding for medical research and development. Non-therapeutic biomolecules are commonly utilized in diagnostic tools and tests, and higher healthcare spending may reflect a stronger emphasis on disease prevention, early detection, and personalized medicine. This heightened focus on diagnostics is likely to contribute to the expansion of the non-therapeutic biomolecules market. For example, in May 2024, the Office for National Statistics, a UK-based statistical authority, reported that healthcare expenditure in the UK reached approximately £292 billion in 2023, marking a nominal increase of 5.6%. Additionally, long-term health and social care spending rose by 2.8% in real terms in 2022. Therefore, the increasing healthcare expenditure is expected to propel the growth of the non-therapeutic biomolecules market during the forecast period.

Product innovation emerges as a prominent trend in the non-therapeutic biomolecules market. Major industry players concentrate on research and development to introduce innovative products, fortifying their market position. An example is BASF SE collaborating with Caregen in January 2022 to unveil the Peptovitae series, employing liposome-encapsulation technology in dermo-cosmetics. This series addresses diverse skin concerns like aging signs, skin brightness enhancement, dryness relief, and moisturization, showcasing the potential of innovative biomolecule applications.

Companies in the non-therapeutic biomolecules sector prioritize developing advanced cell separation technologies for competitive advantage. Notably, Akadeum Life Sciences launched the Microbubble Leukopak Human T Cell Isolation Kit in September 2022, revolutionizing cell separation. This kit utilizes microbubble technology combined with Buoyancy Activated Cell Sorting (BACSTM) Separation Tubes, enhancing productivity by processing double the leukopaks in one-third of the usual time, thereby optimizing laboratory operations.

In October 2022, AbbVie Inc., a U.S.-based healthcare company, acquired DJS Antibodies for $255 million. This acquisition is intended to capitalize on DJS's innovative antibody technology and expertise in developing monoclonal antibodies, thereby accelerating AbbVie's research and development efforts in targeted therapies. DJS Antibodies is a UK-based biopharmaceutical firm that focuses on creating novel monoclonal antibodies for therapeutic applications.

Major companies operating in the non-therapeutic biomolecules market are Amgen Inc., Genentech Inc., Merck KGaA, Lonza Group AG, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Charles River Laboratories International Inc., GE Healthcare Life Sciences, Fujifilm Diosynth Biotechnologies, Evonik Industries AG, Seikagaku Corporation, Takeda Pharmaceutical Company Limited, MilliporeSigma, Covance Inc., Sartorius AG, Sanofi S.A., CordenPharma International, Bayer AG, WuXi AppTec, Ginkgo Bioworks, Synlogic Inc., 3M Company, Eppendorf AG, Medtronic Plc, Bio-Techne Corporation, Iovance Biotherapeutics Inc., Vectalys, Avid Bioservices Inc., Sientra Inc.

Asia-Pacific was the largest region in the non-therapeutic biomolecules market share in 2024. The regions covered in the non-therapeutic biomolecules market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-therapeutic biomolecules market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Non-therapeutic biomolecules encompass a spectrum of organic compounds integral to cellular and organismal functions. These diverse compounds, varying in structure and function, play essential roles in the complex mechanisms governing bodily processes.

The primary classifications of non-therapeutic biomolecules in traditional pharmaceuticals encompass enzymes, recombinant proteins, plasmids, peptides, oligonucleotides, and monoclonal antibodies. Enzymes, for instance, are specialized globular proteins that accelerate biological reactions by lowering the activation energy needed for these processes. These biomolecules find application across diverse sectors including research, pharmaceuticals, and in vitro diagnostics (IVD), contributing significantly to various end-users' operational needs.

The non-therapeutic biomolecules market research report is one of a series of new reports that provides non-therapeutic biomolecules market statistics, including the non-therapeutic biomolecules industry’s global market size, regional shares, competitors with a non-therapeutic biomolecules market share, detailed non-therapeutic biomolecules market segments, market trends, and opportunities, and any further data you may need to thrive in the non-therapeutic biomolecules industry. This non-therapeutic biomolecules market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-therapeutic biomolecule market consists of sales of monosaccharides, disaccharides, polysaccharides, heteropolysaccharides, structural proteins, hormones, respiratory pigments, storage proteins, toxins, deoxyribonucleic acids (DNA), ribonucleic acids (RNA), fatty acids, phospholipids, steroids, eicosanoids, and glycolipids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.